Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission
After a pre-NDA meeting, FDA agreed that Cumberland can submit its application for ifetroban in stages, although the evidence package differs from earlier agency suggestions.
Cumberland Pharmaceuticals has said it intends to submit a new drug application to the US Food and Drug Administration for ifetroban, proposed name DYSCORBAN, in cardiomyopathy associated with Duchenne muscular dystrophy. The company made the announcement on 26 October 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Cumberland Pharmaceuticals Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.